Extreme hypocalcaemia and hyperparathyroidism following denosumab. Is this drug safe in chronic kidney disease?
Nefrologia. 2014;34(4):542-4.
doi: 10.3265/Nefrologia.pre2014.Mar.12383.
[Article in
English,
Spanish]
No abstract available
MeSH terms
-
Aged
-
Bone Density Conservation Agents / adverse effects*
-
Contraindications
-
Denosumab / adverse effects*
-
Female
-
Humans
-
Hyperparathyroidism / chemically induced*
-
Hypocalcemia / chemically induced*
-
Renal Insufficiency, Chronic / complications*
-
Severity of Illness Index
Substances
-
Bone Density Conservation Agents
-
Denosumab